
Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer’s disease (AD) who were α-synuclein positive, a subgroup associated with higher amyloid burden and faster clinical decline
TOKYO and CAMBRIDGE, Mass., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that findings from an analysis of lecanemab-irmb (generic name; U.S. brand name: LEQEMBI®) treatment and α-synuclein (α-Syn) co-pathology* in the cerebrospinal fluid (CSF) substudy of Clarity AD in early Alzheimer’s disease (AD) were presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in Boston and online.
In AD, α-Syn co-pathology may be present alongside amyloid beta (Aβ) and tau pathologies. α-Syn co-pathology may contribute to clinical heterogeneity and disease progression in AD, but its clinical relevance in patients with early AD receiving amyloid-targeting therapy remains unclear. In Clarity AD, lecanemab demonstrated statistically significant slowing of clinical decline in participants with early AD. This post hoc analysis evaluated the prevalence of α-Syn co-pathology and the clinical characteristics associated with α-Syn co-pathology and examined changes over time in clinical assessment scores in the lecanemab and placebo groups in the overall α-Syn-tested group and the α-Syn-positive (α-Syn+) group. These findings were presented in an oral presentation "Lecanemab Treatment and α-Synuclein Co-Pathology in the Clarity AD CSF Substudy" (OC50).